William Blair analyst Brandon Vazquez has maintained their bullish stance on ZTS stock, giving a Buy rating on November 12.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brandon Vazquez has given his Buy rating due to a combination of factors influencing Zoetis’s current and future market position. Despite facing challenges from increased competition and recent commercial setbacks with Librela, Vazquez sees potential for recovery and growth. The upcoming innovation day is anticipated to provide crucial updates on Zoetis’s pipeline and strategies, which could bolster investor confidence.
Vazquez is particularly focused on clinical updates for key products like Librela and Solensia, which could return to growth, and new developments such as Lenivia, which may drive future expansion. Additionally, long-term prospects are promising with potential advancements in oncology and renal therapies. These factors collectively contribute to a positive outlook on Zoetis’s stock, justifying the Buy rating.
In another report released on November 12, BTIG also maintained a Buy rating on the stock with a $160.00 price target.